Peptide Regulatory Landscape
The peptide regulatory landscape is evolving rapidly. The FDA continues to refine its approach to compounded peptides under the FD&C Act, while state boards of pharmacy and medicine issue their own guidance. Providers must stay current on federal scheduling, 503A/503B compounding rules, and state-specific restrictions to maintain compliant practices.
Last updated: March 21, 2026
Active Regulatory Alerts
FDA Peptide Compounding Nominations Under Review
The FDA is actively reviewing nominated peptides for inclusion or removal from the bulk drug substance list under Section 503A/503B. Providers should monitor the FDA's Compounding page for final determinations that may affect prescribing access.
Source: FDA.gov
Tirzepatide Shortage Status Update
The FDA drug shortage database continues to list tirzepatide (Mounjaro/Zepbound) with varying availability. Compounding pharmacies operating under shortage provisions should verify current shortage status before compounding. When a shortage resolves, compounding must cease within a wind-down period.
Source: FDA Drug Shortage Database
DEA Scheduling Considerations for Peptide Practices
While most therapeutic peptides are not scheduled substances, providers should be aware that certain peptide hormones (e.g., synthetic growth hormone analogues) may trigger DEA scrutiny depending on intended use. Maintain thorough documentation of medical necessity for all peptide prescriptions.
Source: DEA Diversion Control
Join 900+ Members in Our Community
Connect with patients, health enthusiasts, and providers discussing peptide therapy, regulatory updates, and the latest research.
Join the CommunityLegal Disclaimer
This page is for educational and informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements change frequently. Providers should consult with qualified legal counsel and verify current regulations with the FDA, their state board of medicine, and state board of pharmacy before making compliance decisions.